What's Hot

    US Stock Futures Signal Strong Open On Budget Bill Cheer – Invesco QQQ Trust, Series 1 (NASDAQ:QQQ), SPDR S&P 500 (ARCA:SPY)

    June 2, 2023

    BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO – BioNTech (NASDAQ:BNTX)

    June 2, 2023

    Worried About Paying for Healthcare in Retirement? Here Are Some Key Moves to Make.

    June 2, 2023
    Facebook Twitter Instagram YouTube LinkedIn TikTok Telegram
    Telegram
    InformatemiInformatemi
    Subscribe
    • Home
    • Blog
    • Contact
    InformatemiInformatemi
    Home » Blog » CHARLES RIVER LABORATORIES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Charles River Laboratories International, Inc. – CRL – Charles River (NYSE:CRL)
    Press Releases

    CHARLES RIVER LABORATORIES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Charles River Laboratories International, Inc. – CRL – Charles River (NYSE:CRL)

    PRNewswireBy PRNewswireMay 27, 20233 Mins Read
    Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email
    Share
    Facebook Twitter LinkedIn Pinterest Email


    NEW ORLEANS, May 26, 2023 /PRNewswire/ — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 18, 2023 to file lead plaintiff applications in a securities class action lawsuit against Charles River Laboratories International, Inc. CRL, if they purchased the Company’s securities between May 5, 2020 and February 21, 2023, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Massachusetts.

    What You May Do

    If you purchased securities of Charles River and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nyse-crl/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by July 18, 2023.

    About the Lawsuit

    Charles River and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. 

    On February 22, 2023, pre-market, the Company disclosed that it had received a subpoena from the U.S. Department of Justice relating to an ongoing investigation in conjunction with the U.S. Fish and Wildlife Service into the supply chain and illegal importation of non-human primates for research, and that the Company voluntarily suspended shipments of primates from Cambodia, which would negatively impact its earnings for the year and would reduce revenue growth by 200 basis points to 400 basis points.

    On this news, shares of Charles River fell $24.51, or 10%, to close at $219.09 per share on February 22, 2023, on unusually heavy trading volume.

    The case is Coleman v. Charles River Laboratories International, Inc., et al., No. 23-cv-11132.

    About Kahn Swick & Foti, LLC

    KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, California, Louisiana and New Jersey.

    To learn more about KSF, you may visit http://ksfcounsel.com/.

    Contact:

    Kahn Swick & Foti, LLC
    Lewis Kahn, Managing Partner
    lewis.kahn@ksfcounsel.com
    1-877-515-1850
    1100 Poydras St., Suite 960
    New Orleans, LA 70163

    View original content to download multimedia:https://www.prnewswire.com/news-releases/charles-river-laboratories-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick–foti-llc-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-charles-river-301836095.html

    SOURCE Kahn Swick & Foti, LLC



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleJMP Securities Initiates Coverage of Physicians Realty Trust (DOC) with Market Outperform Recommendation
    Next Article GI society statement: UHC offers to trade GI prior auth for a poorly defined alternative
    PRNewswire

    Related Posts

    BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO – BioNTech (NASDAQ:BNTX)

    June 2, 2023

    Sprout Pharmaceuticals Announces Release of Abstract Reporting Positive Interim Results for Flibanserin in Breast Cancer Patients Suffering from Low Libido for Poster Discussion at 2023 ASCO Annual Meeting

    June 2, 2023

    SI Tickets by Sports Illustrated Brings Live Event Tickets to SuperWorld

    June 2, 2023
    Top Posts

    Worried About Paying for Healthcare in Retirement? Here Are Some Key Moves to Make.

    June 2, 2023

    The Good News (and Bad) About HP’s Q2

    June 2, 2023

    Safety First!! – Autoliv Plans Launch Its First Motorcycle Airbag In 2025 – Autoliv (NYSE:ALV)

    June 2, 2023

    Subscribe to Updates

    Discover hidden stock market gems and stay up to date with our weekly email newsletter and individual stock ideas

    Loading

    Gain access to our Newsletter, SMS Alerts, and Telegram Community for FREE

    Top Insights

    US Stock Futures Signal Strong Open On Budget Bill Cheer – Invesco QQQ Trust, Series 1 (NASDAQ:QQQ), SPDR S&P 500 (ARCA:SPY)

    June 2, 2023

    BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO – BioNTech (NASDAQ:BNTX)

    June 2, 2023

    Worried About Paying for Healthcare in Retirement? Here Are Some Key Moves to Make.

    June 2, 2023
    Get Informed

    Subscribe to Updates

    Discover hidden stock market gems and stay up to date with our weekly email newsletter and individual stock ideas

    Loading
    Facebook Twitter Instagram YouTube LinkedIn TikTok
    • Privacy Policy
    • Disclaimer
    • SMS Squeeze
    • Sign Up
    © 2023 Informatemi

    Type above and press Enter to search. Press Esc to cancel.